Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18277Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Koutras, A. K. | en |
| dc.contributor.author | Antonacopoulou, A. G. | en |
| dc.contributor.author | Eleftheraki, A. G. | en |
| dc.contributor.author | Dimitrakopoulos, F. I. | en |
| dc.contributor.author | Koumarianou, A. | en |
| dc.contributor.author | Varthalitis, I. | en |
| dc.contributor.author | Fostira, F. | en |
| dc.contributor.author | Sgouros, J. | en |
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Bournakis, E. | en |
| dc.contributor.author | Bafaloukos, D. | en |
| dc.contributor.author | Bompolaki, I. | en |
| dc.contributor.author | Galani, E. | en |
| dc.contributor.author | Kalogeras, K. T. | en |
| dc.contributor.author | Pectasides, D. | en |
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Kalofonos, H. P. | en |
| dc.date.accessioned | 2015-11-24T18:51:34Z | - |
| dc.date.available | 2015-11-24T18:51:34Z | - |
| dc.identifier.issn | 1473-1150 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18277 | - |
| dc.rights | Default Licence | - |
| dc.title | Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1038/tpj.2011.37 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21844885 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2011 | - |
| heal.abstract | The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This study compared two chemotherapy regimens (FOLFIRI versus XELIRI) combined with bevacizumab, as first-line treatment for metastatic colorectal cancer. DNA was extracted from blood samples of 173 patients participating in the trial. Genotyping was performed for selected SNPs (VEGF-1154, +936, -634, -2578 and -1498). All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate (RR). There were no significant differences with respect to the distribution of genotypes in the treatment groups. The VEGF-1154 GG genotype was more frequent in patients not responding to treatment compared with responders (65.5 versus 39.8%, P=0.032). Furthermore, the VEGF-1154 GG genotype was associated with inferior median OS compared with GA (hazards ratio=1.68; 95% confidence interval: 1.10-2.57; P=0.016) or with the alternative genotypes (GA and AA) combined (hazards ratio=1.62; 95% confidence interval: 1.09-2.40; P=0.017). In multivariate analysis, the VEGF-1154 GG genotype remained a significant adverse factor for OS. Our results support the potential predictive ability of VEGF genotypes in patients with metastatic colorectal cancer receiving irinotecan-based chemotherapy plus bevacizumab, in terms of RR and OS. However, current results should be validated prospectively, in larger cohorts.The Pharmacogenomics Journal advance online publication, 16 August 2011; doi:10.1038/tpj.2011.37. | en |
| heal.journalName | Pharmacogenomics J | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
